DEXTROGEL FAST ACTING DEXTROSE GEL 3 X 25G - 1 BOX

Product Information

The following adverse reactions have also been reported in association with systemic oestrogen/ progestogen treatment: Low blood glucose levels (hypoglycaemia) in newborn infants are common and occur frequently in certain at‐risk groups (infants of mothers with high blood glucose levels (diabetes), infants born preterm, small and large infants). Infants with low blood glucose levels are at higher risk for developmental problems later in childhood. To manage this condition, active treatments are generally used, frequently requiring the use of formula milk or admission to the neonatal intensive care unit to receive fluid infusion into the veins, resulting in temporary separation from the mother. Sugar gel applied to the inside of the mouth is a simple and low‐cost option for the initial care of infants with low blood glucose levels. We are exploring whether oral dextrose is more effective than no treatment or other active treatments in correcting low blood glucose levels in newborn infants and reducing its long‐term effects on neurodevelopment. Investigators in a randomised trial assessed intravenous dextrose and glucagon (200 ug/kg) or intragastric medium chain triglycerides (5 mL/kg) ( Hawdon 1993). Both treatments substantially increased the blood glucose concentration among infants already receiving 5 mcg/kg/min intravenous dextrose for hypoglycaemia. Pharmacokinetic studies indicate that, when applied topically to a large area of skin in a volatile solvent, approximately 10% of the oestradiol is percutaneously absorbed into the vascular system, regardless of the age of the patient.

Risk in the intervention group (and its 95% confidence interval) is based on assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) We included two studies conducted in high-income countries, involving 312 late preterm and at-risk term infants and comparing oral dextrose gel (40% concentration) to placebo gel. One study was at low risk of bias, and the other (an abstract) was at unclear to high risk of bias. Oral dextrose gel compared with placebo gel probably increases correction of hypoglycaemic events (rate ratio 1.08, 95% confidence interval (CI) 0.98 to 1.20; rate difference 66 more per 1000, 95% CI 17 fewer to 166 more; 1 study; 237 infants; moderate-certainty evidence), and may result in a slight reduction in the risk of major neurological disability at age two years or older, but the evidence is uncertain (risk ratio (RR) 0.46, 95% CI 0.09 to 2.47; risk difference (RD) 24 fewer per 1000, 95% CI 41 fewer to 66 more; 1 study, 185 children; low-certainty evidence). The evidence is very uncertain about the effect of oral dextrose gel compared with placebo gel or no gel on the need for intravenous treatment for hypoglycaemia (RR 0.78, 95% CI 0.46 to 1.32; RD 37 fewer per 1000, 95% CI 91 fewer to 54 more; 2 studies, 312 infants; very low-certainty evidence). Investigators in one study of 237 infants reported no adverse events (e.g. choking or vomiting at the time of administration) in the oral dextrose gel or placebo gel group (low-certainty evidence).

Help page

Switching from a continuous oestrogen-progestogen combined HRT: treatment with Oestrogel can be started on any day of the cycle. The WHI trial found no increase in the risk of breast cancer in hysterectomised women using oestrogen-only HRT. Observational studies have mostly reported a small increase in risk of having breast cancer diagnosed that is lower than that found in users of oestrogen-progestogen combinations (see section 4.8). Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition. Dextrose injection is given through an IV into a vein. Do not inject this medicine into a muscle or under the skin. The injection should be given only as an intravenous (IV) injection and should be given slowly. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when Dextrose is injected. The overall evidence shows an increased risk of breast cancer in women taking combined oestrogen-progestogen or oestrogen-only HRT, that is dependent on the duration of taking HRT.

Weston P, Harris D, Harding J. Dextrose gel and formula but not breast milk are effective treatments for neonatal hypoglycaemia. Journal of Paediatrics and Child Health 2017; 53( Suppl 2):112. [DOI: 10.1111/jpc.13494_330] [ CrossRef] [ Google Scholar] Absolute risk estimations based on results of the largest randomised placebo-controlled trial (WHI-study) and the largest meta-analysis of prospective epidemiological studies are presented. Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones. Herbal preparations containing St John's wort (Hypericum perforatum) may induce the metabolism of oestrogens.Oral dextrose gel is probably an effective and safe first-line treatment for infants with neonatal hypoglycaemia in high-income settings.

Oral dextrose gel (specifically 40% dextrose concentration) used to treat hypoglycaemia in newborn infants (specifically at‐risk late preterm and term infants) probably increases correction of hypoglycaemic events, and may result in a slight reduction in the risk of major neurological disability at age two years or older. Oral dextrose gel treatment probably reduces the incidence of separation from the mother for treatment and increases the likelihood of exclusive breastfeeding after discharge. No adverse events have been reported. Results suggest that oral dextrose gel probably corrects individual episodes of low blood glucose levels and may result in a slight reduction in the risk of major disability at age two years or older; however, the evidence is uncertain. The evidence was not sufficient to show whether oral dextrose gel reduces the need for other treatments. Oral dextrose gel compared to placebo gel probably reduces mother‐infant separation and probably increases the likelihood of exclusive breastfeeding after discharge from the hospital. Researchers reported no adverse eventswhen oral dextrose gel was given to infants. Randomised controlled data found no increased risk of CAD in hysterectomised women using oestrogen-only therapy. Maximum serum concentrations (C max) of oestradiol and estrone on Day 12 were 117 pg/ml and 128 pg/ml, respectively.tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your